thromboxane-b2 and beta-Thalassemia

thromboxane-b2 has been researched along with beta-Thalassemia* in 2 studies

Other Studies

2 other study(ies) available for thromboxane-b2 and beta-Thalassemia

ArticleYear
A chronic hypercoagulable state in patients with beta-thalassaemia major is already present in childhood.
    British journal of haematology, 1999, Volume: 107, Issue:4

    A higher than normal incidence of thromboembolic events has been observed in adult patients with beta-thalassaemia major (TM) and certain haemostatic anomalies found in these patients suggest the existence of a chronic hypercoagulable state. Thalassaemic red blood cells (RBC) were demonstrated to facilitate thrombin formation due to altered asymmetry of the membrane phospholipids with enhanced exposure of phosphatidylserine. Since RBC anomalies exist in thalassaemia from the first months of life, we studied markers of hypercoagulability and thrombophilia in 36 adult patients (range 19-38 years) and 26 children (range 2-18 years) with beta-TM. All the patients were in steady state and none had experienced clinical signs or symptoms of thrombosis. Highly elevated urinary levels of 11-dehydro-thromboxane B2 and significantly elevated plasma levels of thrombin-antithrombin III (TAT) complexes were observed to the same extent in TM children and adults. The levels of factor II were decreased while factors V, VII + X and plasminogen were within the normal range. The natural coagulation inhibitors, protein C (PC) and protein S (PS) were significantly decreased in all TM patients investigated, regardless of age, but the PS binding protein (C4bBP) and antithrombin III levels were normal. The frequency of other thrombophilic mutations was not increased. Thus, a chronic hypercoagulable state already exists in thalassaemia in childhood and may contribute to the cardiac and pulmonary anomalies and the thrombotic events which occur later.

    Topics: Adolescent; Adult; beta-Thalassemia; Blood Coagulation Factors; Child; Child, Preschool; Complement Inactivator Proteins; Glycoproteins; Humans; Mutation; Plasminogen; Prostaglandins F, Synthetic; Protein C; Protein S; Receptors, Complement; Thrombophilia; Thromboxane B2

1999
Pathogenesis of hypoxemia.
    The Southeast Asian journal of tropical medicine and public health, 1992, Volume: 23 Suppl 2

    Thrombocytosis and morphological changes in shape and size of circulating platelets are commonly found in splenectomized thalassemia patients. Functional abnormalities of the platelets are evidently related to their fragile nature. Spontaneous aggregation of platelets can easily occur following application of mild pressure either from a stirring magnetic bar or due to centrifugal force. Platelets are hyper-reactive to chemical stimulation and the release of platelet granule contents (eg ATP) together with other membranous lipid metabolites, thromboxane A2 and malondialdehyde is markedly enhanced. The lipid soluble antioxidant, vitamin E is depleted from various blood compartments. The findings suggest that circulating platelets in splenectomized thalassemia are continuously attacked by yet to be identified blood borne factor(s) and the defective platelets could play a pivotal role in the pathogenesis of hypoxemia.

    Topics: beta-Thalassemia; Case-Control Studies; Hemoglobin E; Hemoglobinopathies; Humans; Hypoxia; Incidence; Malondialdehyde; Platelet Aggregation; Platelet Count; Postoperative Complications; Splenectomy; Thailand; Thromboxane B2; Vitamin E

1992